Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death

[1]  G. Roboz.  Current treatment of acute myeloid leukemia , 2012, Current opinion in oncology.

[2]  David A. Williams,et al.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.

[3]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[4]  Wei Li,et al.  An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro , 2011, Molecular and Cellular Biochemistry.

[5]  David A. Williams,et al.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. , 2011, Blood.

[6]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[7]  K. Lackner,et al.  Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity , 2011, Cell Death and Disease.

[8]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Hess,et al.  MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. , 2011, Experimental hematology.

[10]  Todd D. Westergard,et al.  Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint , 2010, Nature.

[11]  Jiaying Tan,et al.  The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.

[12]  Tatsushi Yoshida,et al.  Blockade of Rac1 Activity Induces G1 Cell Cycle Arrest or Apoptosis in Breast Cancer Cells through Downregulation of Cyclin D1, Survivin, and X-Linked Inhibitor of Apoptosis Protein , 2010, Molecular Cancer Therapeutics.

[13]  J. Liao,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[14]  N. Klugbauer,et al.  The Nuclear Import of the Small GTPase Rac1 is Mediated by the Direct Interaction with Karyopherin α2 , 2010, Traffic.

[15]  H. Shimokawa,et al.  Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[16]  M. Wunderlich,et al.  Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling , 2008, Cell cycle.

[17]  George Iliakis,et al.  γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin , 2008, Nucleic acids research.

[18]  U. Knaus,et al.  P21-activated kinase is required for mitotic progression and regulates Plk1 , 2008, Oncogene.

[19]  D. Williams,et al.  Rac guanosine triphosphatases represent a potential target in AML , 2008, Leukemia.

[20]  Yi Zheng,et al.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.

[21]  David A. Williams,et al.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis , 2008, Leukemia.

[22]  Jinshui Fan,et al.  Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. , 2008, Blood.

[23]  C. Der,et al.  Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. , 2008, Methods in enzymology.

[24]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[25]  C. Der,et al.  Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.

[26]  John G. Collard,et al.  Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.

[27]  David A. Williams,et al.  Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. , 2007, Cancer cell.

[28]  K. Cimprich,et al.  The ATR pathway: fine-tuning the fork. , 2007, DNA repair.

[29]  Hans Joenje,et al.  Fanconi anemia and DNA replication repair. , 2007, DNA repair.

[30]  J. Carroll,et al.  Rac activity is polarized and regulates meiotic spindle stability and anchoring in mammalian oocytes. , 2007, Developmental cell.

[31]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[32]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[33]  A. Ridley,et al.  Rho GTPases and cell cycle control , 2006, Growth factors.

[34]  F. Dammacco,et al.  Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. , 2005, Carcinogenesis.

[35]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[36]  U. Laufs,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[37]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[38]  M. Minden,et al.  Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis , 2004, Cancer Research.

[39]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[40]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Lacal,et al.  Rho GTPases: potential candidates for anticancer therapy. , 2004, Cancer letters.

[42]  P. Jeggo,et al.  ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation , 2004, Cancer Research.

[43]  R. Bonfil,et al.  Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma , 1999, Clinical & Experimental Metastasis.

[44]  P. Olive.  Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. , 2004, Methods in cell biology.

[45]  W. Hiddemann,et al.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. , 2003, Blood.

[46]  Kai Rothkamm,et al.  Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[48]  B. Halmos,et al.  Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. , 2002, Carcinogenesis.

[49]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[50]  M. Minden,et al.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.

[51]  S. Coniglio,et al.  Rac1 Protects Epithelial Cells against Anoikis* , 2001, The Journal of Biological Chemistry.

[52]  L. Van Aelst,et al.  Rho GTPases: signaling, migration, and invasion. , 2000, Experimental cell research.

[53]  M. Jakóbisiak,et al.  Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Zhenbiao Yang,et al.  RHO Gtpases and the Actin Cytoskeleton , 2000 .

[55]  G. Bokoch,et al.  Regulation of cell function by rho family GTPases , 2000, Immunologic research.

[56]  T. Rabbitts,et al.  The Mll–AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis , 1999, The EMBO journal.

[57]  M. Minden,et al.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.

[58]  K. Keyomarsi,et al.  Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 , 1998, Oncogene.

[59]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[60]  M. Kastan,et al.  Three paths to stress relief , 1996, Nature.

[61]  M. Karin,et al.  Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.

[62]  P. Crespo,et al.  The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.

[63]  J. Rowley,et al.  Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II , 1993 .